Gostick N, James I G, Khong T K, Roy P, Shepherd P R, Miller A J
Medical Department, Napp Laboratories Ltd., Cambridge, England.
Curr Med Res Opin. 1990;12(3):135-42. doi: 10.1185/03007999009111494.
A double-blind, crossover study was undertaken in general practice to compare the efficacy and tolerability of a new controlled-release indomethacin with sustained-release diclofenac sodium in patients with osteoarthritis. Eighty-four patients were randomly allocated to receive controlled-release indomethacin tablets (75 mg) or sustained-release diclofenac sodium tablets (100 mg) at night for a period of 4 weeks before being crossed-over to receive the alternative treatment for a further 4 weeks. Pain scores for day and night, duration of morning stiffness, requirement for escape analgesia, and treatment preference were similar for both treatments. There was no significant difference between treatments for incidence and severity of side-effects. It was concluded that controlled-release indomethacin tablets (75 mg) given as a single night-time dose were as efficacious and well tolerated as sustained-release diclofenac sodium (100 mg).
在普通医疗实践中进行了一项双盲交叉研究，以比较新型缓释吲哚美辛与缓释双氯芬酸钠在骨关节炎患者中的疗效和耐受性。84名患者被随机分配，在夜间服用缓释吲哚美辛片（75毫克）或缓释双氯芬酸钠片（100毫克），为期4周，之后交叉接受另一种治疗，再持续4周。两种治疗的日夜疼痛评分、晨僵持续时间、急救镇痛需求和治疗偏好相似。两种治疗在副作用的发生率和严重程度上没有显著差异。得出的结论是，每晚单次服用75毫克的缓释吲哚美辛片与100毫克的缓释双氯芬酸钠疗效相当且耐受性良好。
